within Pharmacolibrary.Drugs.ATC.J;

model J05AR10
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 7.666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0237,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.017166666666666667,
    Tlag           = 4.8,            
    Vdp             = 0.056100000000000004,
    k12             = 10,
    k21             = 10
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AR10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lopinavir and ritonavir is a fixed-dose combination of antiretroviral drugs used in the treatment and prevention of HIV/AIDS. Lopinavir inhibits the HIV-1 protease, while ritonavir acts mainly as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A-mediated metabolism of lopinavir, thereby increasing lopinavir plasma concentrations. This combination is approved and is a common part of highly active antiretroviral therapy (HAART) regimens used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects (both sexes) after oral administration of lopinavir/ritonavir 400 mg/100 mg twice daily in tablet formulation.</p><h4>References</h4><ol><li><p>Lê, MP, et al., &amp; Timsit, JF (2020). Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients. <i>The Journal of antimicrobial chemotherapy</i> 75(9) 2657–2660. DOI:<a href=\"https://doi.org/10.1093/jac/dkaa261\">10.1093/jac/dkaa261</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32688374/\">https://pubmed.ncbi.nlm.nih.gov/32688374</a></p></li><li><p>Kaufmann, P, et al., &amp; Dingemanse, J (2015). Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. <i>British journal of clinical pharmacology</i> 80(4) 670–677. DOI:<a href=\"https://doi.org/10.1111/bcp.12650\">10.1111/bcp.12650</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25851691/\">https://pubmed.ncbi.nlm.nih.gov/25851691</a></p></li><li><p>Zhang, C, et al., &amp; Denti, P (2012). Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. <i>Antiviral therapy</i> 17(1) 25–33. DOI:<a href=\"https://doi.org/10.3851/IMP1915\">10.3851/IMP1915</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22267466/\">https://pubmed.ncbi.nlm.nih.gov/22267466</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AR10;
